Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686920 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
A Phase 3 study of Hepatic Encephalopathy, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 322
- Enrollment target
- 20
- Study locations
NCT00686920 is a Phase 3 study of Hepatic Encephalopathy that has completed, run by Bausch Health Americas. The registered enrollment target is 322 participants, above the 150-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (115% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00686920, a Phase 3 study of Hepatic Encephalopathy, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 322 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
Conditions Studied
Interventions
- DRUG Rifaximin
Study Locations (20)
California
- - Aurora
- - Fresno
- - La Jolla
- - Long Beach
- - Los Angeles
- - Merced
- - Sacramento
- - San Francisco
New York
- - Bayside
- - New York
Alabama
- - Birmingham
Colorado
- - Golden
District of Columbia
- - Washington D.C.
Georgia
- - Macon
Iowa
- - Iowa City
Louisiana
- - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2007-03-07 |
| Est. Completion | 2010-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686920
The ClinicalTrials.gov registry entry for NCT00686920 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (115% higher). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which Rifaximin is the first listed.
NCT00686920 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT00686920 about?
NCT00686920 is a clinical study titled "Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy". This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
What is the current status of trial NCT00686920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 322 participants. The study started on 2007-03-07. Estimated completion is 2010-12-08.
What conditions does trial NCT00686920 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy.
What interventions are being tested in trial NCT00686920?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT00686920?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00686920 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
ACTIVE NOT RECRUITING · Phase 3
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
TReatment for ImmUne Mediated PathopHysiology
RECRUITING · Phase 2
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.